転移性黒色腫治療薬の世界市場レポート 2025年

転移性黒色腫治療薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.1％で147億1,000万米ドルに成長します。予測期間の成長は、患者プールの拡大、研究開発イニシアティブ、バイオマーカーの同定、規制当局の承認促進、新興経済諸国への市場拡大などに起因しています。予測期間における主な動向としては、免疫療法の併用、精密医療の進歩、新たな標的療法、手術後の補助療法、二重特異性抗体の開発などが挙げられます。

転移性黒色腫治療薬市場の成長は、2つの重要な要因によって促進されると予想されます。第一に、メラノーマの罹患率の上昇が市場拡大に寄与する見通しです。メラノーマは、皮膚の色素調整細胞であるメラノサイトに発生する皮膚がんの一種で、皮膚のどこにでも発生する可能性があります。転移性黒色腫治療薬は、変異化学物質をブロックし、健康な組織への害を最小限に抑えながらメラノーマ細胞の増殖を阻害するように設計された様々な治療を包含します。米国がん協会によると、2023年に米国で新たに診断されるメラノーマの症例数は、男性で58,120例、女性で39,490例、合計約97,610例となり、約7,990人が死亡すると予測されています。メラノーマの罹患率の上昇は、転移性黒色腫治療薬市場成長の主要な促進要因です。

生物製剤に対する需要の高まりは、市場成長をさらに促進すると予想されます。生物学的製剤は、生物に由来する、または生物の成分を含む治療製品であり、転移性黒色腫の治療状況を一変させました。生物学的製剤は、従来の化学療法と比較して、副作用を最小限に抑えながら患者の転帰を著しく改善する、標的療法と免疫療法に基づくアプローチを提供します。例えば、米国食品医薬品局によると、2022年末までに40のバイオシミラーが承認され、そのうち27が米国で販売され、10種類の先発バイオ製剤の代替品となっています。標的療法や免疫療法の利点を持つ生物製剤の需要拡大は、転移性黒色腫治療薬市場の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界転移性黒色腫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の転移性黒色腫治療薬市場：成長率分析
• 世界の転移性黒色腫治療薬市場の実績：規模と成長, 2019-2024
• 世界の転移性黒色腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界転移性黒色腫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の転移性黒色腫治療薬市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 免疫療法
• 標的療法
• 放射線治療
• 手術
• 世界の転移性黒色腫治療薬市場ステージ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ステージ0
• ステージI
• ステージ II
• ステージIII
• ステージIV
• 世界の転移性黒色腫治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 在宅ヘルスケア
• その他のエンドユーザー
• 世界の転移性黒色腫治療薬市場化学療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• ダカルバジン
• テモゾロミド
• カルボプラチンとシスプラチンの併用
• 世界の転移性黒色腫治療薬市場、免疫療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チェックポイント阻害剤
• インターロイキン-2（IL-2）
• 腫瘍溶解性ウイルス療法
• 世界の転移性黒色腫治療薬市場、標的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• BRAF阻害剤
• MEK阻害剤
• KIT阻害剤
• 世界の転移性黒色腫治療薬市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 定位放射線手術
• 緩和放射線療法
• 世界の転移性黒色腫治療薬市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍切除
• センチネルリンパ節生検
• 減量手術

第7章 地域別・国別分析

• 世界の転移性黒色腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の転移性黒色腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 転移性黒色腫治療薬市場：競合情勢
• 転移性黒色腫治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Daiichi Sankyo Company Ltd.
• Eisai Co. Ltd.
• Incyte Corporation
• Exelixis Inc.
• BeiGene Ltd
• Immunocore Holdings plc
• Genentech Inc.
• Iovance Biotherapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 転移性黒色腫治療薬市場2029：新たな機会を提供する国
• 転移性黒色腫治療薬市場2029：新たな機会を提供するセグメント
• 転移性黒色腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Metastatic melanoma therapeutics encompass a range of treatment options available for individuals diagnosed with metastatic melanoma, a type of skin cancer that has spread to other parts of the body. Melanoma arises from the transformation of pigmented cells called melanocytes, leading to the formation of tumors.

The primary types of metastatic melanoma therapeutics include chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgery. Chemotherapy involves the use of potent chemicals to eliminate rapidly proliferating cells in the body. The treatment may be administered at various stages, including stage 0, stage I, stage II, stage III, and stage IV, depending on the extent of the cancer. These therapeutic options are utilized by various healthcare providers, including hospitals, specialty clinics, home healthcare, and other medical facilities.

The metastatic melanoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides metastatic melanoma therapeutics market statistics, including metastatic melanoma therapeutics industry global market size, regional shares, competitors with a metastatic melanoma therapeutics market share, detailed metastatic melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic melanoma therapeutics industry. This metastatic melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic melanoma therapeutics market size has grown rapidly in recent years. It will grow from $8.28 billion in 2024 to $9.31 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to pioneering immunotherapy approval, targeted therapy innovations, clinical trial successes, introduction of combination therapies, advancements in diagnostic technologies

The metastatic melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $14.71 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to expanding patient pool, research and development initiatives, biomarker identification, accelerated regulatory approvals, market expansion into emerging economies. Major trends in the forecast period include immunotherapy combinations, precision medicine advances, emerging targeted therapies, adjuvant therapies after surgery, development of bi-specific antibodies.

The anticipated growth in the metastatic melanoma therapeutics market is expected to be propelled by two significant factors. Firstly, the rising incidence of melanoma cases is poised to contribute to market expansion. Melanoma, a form of skin cancer originating in melanocytes, the pigment-regulating cells in the skin, can occur anywhere on the skin. Metastatic melanoma therapeutics encompass various treatments designed to block mutant chemicals and impede the growth of melanoma cells while minimizing harm to healthy tissue. According to the American Cancer Society, it is estimated that there will be 58,120 new cases of melanomas diagnosed in males and 39,490 in females in the US in 2023, totaling around 97,610 cases, with approximately 7,990 predicted deaths. The rising incidence of melanoma is a key driver for the growth of the metastatic melanoma therapeutics market.

The growing demand for biologics is expected to further propel market growth. Biologics, therapeutic products derived from living organisms or containing components of living organisms, have transformed the treatment landscape for metastatic melanoma. They offer targeted and immunotherapy-based approaches that have significantly improved patient outcomes with minimal side effects compared to traditional chemotherapy. For instance, according to the US Food and Drug Administration reported that by the end of 2022, 40 biosimilars had received approval, with 27 of them available in the United States, providing alternatives to 10 brand-name biologics. The growing demand for biologics, with their targeted and immunotherapy benefits, is a significant driver for the metastatic melanoma therapeutics market.

The metastatic melanoma therapeutics market is currently witnessing a significant trend towards product innovations, with companies strategically leveraging recent technologies to enhance their market standing. Notably, in January 2022, UK-based biotechnology firm Immunocore obtained FDA approval for KIMMTRAK, the first-ever FDA-approved T cell receptor (TCR) therapy designed for treating unresectable or metastatic uveal melanoma. Developed using Immunocore's ImmTAC technology platform, KIMMTRAK demonstrated a noteworthy overall survival (OS) advantage, boasting a hazard ratio of 0.51 and a median OS of nearly 22 months.

Leading companies in the metastatic melanoma therapeutics sector are actively engaging in strategic collaborations to assess treatments for metastatic cutaneous melanoma. An example of this is the collaboration between Immunocore and Sanofi, announced in June 2022. The partnership involves a clinical trial collaboration and supply agreement, wherein Sanofi will evaluate its engineered IL-2, SAR444245, in combination with Immunocore's KIMMTRAK in patients with advanced unresectable or metastatic skin cancers.

In April 2022, Germany-based investment firm EMZ Partners acquired a majority stake in FotoFinder Systems GmbH, a move undisclosed in terms of financial details. This strategic partnership aims to facilitate FotoFinder Systems GmbH's expansion of its product portfolio and market reach. FotoFinder Systems GmbH specializes in providing skin visualization equipment utilized in melanoma therapeutics.

Major companies operating in the metastatic melanoma therapeutics market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc., BeiGene Ltd, Immunocore Holdings plc, Genentech Inc., Iovance Biotherapeutics Inc., Nektar Therapeutics, Adaptimmune Therapeutics plc, AIVITA Biomedical Inc., Idera Pharmaceuticals Inc., Evaxion Biotech A/S, AB Science, AgonOX Inc., InxMed Co. Ltd., NewLink Genetics Corporation, Vical Inc.

North America was the largest region in the metastatic melanoma therapeutics market in 2024. The regions covered in the metastatic melanoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the metastatic melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic melanoma therapeutics market consists of sales of surgical resection, lymph node dissection, and lymphatic mapping and sentinel lymph node biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic melanoma therapeutics market also includes sales of trametinib (Mekinist), cobimetinib (Cotellic), and binimetinib (Mektovi). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Melanoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic melanoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic melanoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic melanoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy; Surgery
• 2) By Stages: Stage 0; Stage I; Stage II; Stage III; Stage IV
• 3) By End User: Hospitals; Specialty Clinics; Home Healthcare; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Dacarbazine; Temozolomide; Carboplatin And Cisplatin Combinations
• 2) By Immunotherapy: Checkpoint Inhibitors; Interleukin-2 (IL-2); Oncolytic Virus Therapies
• 3) By Targeted Therapy: BRAF Inhibitors; MEK Inhibitors; KIT Inhibitors
• 4) By Radiation Therapy: Stereotactic Radiosurgery; Palliative Radiation Therapy
• 5) By Surgery: Tumor Resection; Sentinel Lymph Node Biopsy; Debulking Surgery
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Melanoma Therapeutics Market Characteristics

3. Metastatic Melanoma Therapeutics Market Trends And Strategies

4. Metastatic Melanoma Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Metastatic Melanoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Melanoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Melanoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Metastatic Melanoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Melanoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Melanoma Therapeutics Total Addressable Market (TAM)

6. Metastatic Melanoma Therapeutics Market Segmentation

• 6.1. Global Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery
• 6.2. Global Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stage 0
• Stage I
• Stage II
• Stage III
• Stage IV
• 6.3. Global Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Home Healthcare
• Other End-Users
• 6.4. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dacarbazine
• Temozolomide
• Carboplatin And Cisplatin Combinations
• 6.5. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Interleukin-2 (IL-2)
• Oncolytic Virus Therapies
• 6.6. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BRAF Inhibitors
• MEK Inhibitors
• KIT Inhibitors
• 6.7. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stereotactic Radiosurgery
• Palliative Radiation Therapy
• 6.8. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Resection
• Sentinel Lymph Node Biopsy
• Debulking Surgery

7. Metastatic Melanoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Metastatic Melanoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Melanoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Melanoma Therapeutics Market

• 8.1. Asia-Pacific Metastatic Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Melanoma Therapeutics Market

• 9.1. China Metastatic Melanoma Therapeutics Market Overview
• 9.2. China Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Melanoma Therapeutics Market

• 10.1. India Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Melanoma Therapeutics Market

• 11.1. Japan Metastatic Melanoma Therapeutics Market Overview
• 11.2. Japan Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Melanoma Therapeutics Market

• 12.1. Australia Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Melanoma Therapeutics Market

• 13.1. Indonesia Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Melanoma Therapeutics Market

• 14.1. South Korea Metastatic Melanoma Therapeutics Market Overview
• 14.2. South Korea Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Melanoma Therapeutics Market

• 15.1. Western Europe Metastatic Melanoma Therapeutics Market Overview
• 15.2. Western Europe Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Melanoma Therapeutics Market

• 16.1. UK Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Melanoma Therapeutics Market

• 17.1. Germany Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Melanoma Therapeutics Market

• 18.1. France Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Melanoma Therapeutics Market

• 19.1. Italy Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Melanoma Therapeutics Market

• 20.1. Spain Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Melanoma Therapeutics Market

• 21.1. Eastern Europe Metastatic Melanoma Therapeutics Market Overview
• 21.2. Eastern Europe Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Melanoma Therapeutics Market

• 22.1. Russia Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Melanoma Therapeutics Market

• 23.1. North America Metastatic Melanoma Therapeutics Market Overview
• 23.2. North America Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Melanoma Therapeutics Market

• 24.1. USA Metastatic Melanoma Therapeutics Market Overview
• 24.2. USA Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Melanoma Therapeutics Market

• 25.1. Canada Metastatic Melanoma Therapeutics Market Overview
• 25.2. Canada Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Melanoma Therapeutics Market

• 26.1. South America Metastatic Melanoma Therapeutics Market Overview
• 26.2. South America Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Melanoma Therapeutics Market

• 27.1. Brazil Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Melanoma Therapeutics Market

• 28.1. Middle East Metastatic Melanoma Therapeutics Market Overview
• 28.2. Middle East Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Melanoma Therapeutics Market

• 29.1. Africa Metastatic Melanoma Therapeutics Market Overview
• 29.2. Africa Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Melanoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Melanoma Therapeutics Market Competitive Landscape
• 30.2. Metastatic Melanoma Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Melanoma Therapeutics Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. GlaxoSmithKline PLC
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Daiichi Sankyo Company Ltd.
• 31.9. Eisai Co. Ltd.
• 31.10. Incyte Corporation
• 31.11. Exelixis Inc.
• 31.12. BeiGene Ltd
• 31.13. Immunocore Holdings plc
• 31.14. Genentech Inc.
• 31.15. Iovance Biotherapeutics Inc.

32. Global Metastatic Melanoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Melanoma Therapeutics Market

34. Recent Developments In The Metastatic Melanoma Therapeutics Market

35. Metastatic Melanoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Melanoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Melanoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Melanoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer